FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323528474> ?p ?o ?g. }

• W4323528474 endingPage "173" @default.
• W4323528474 startingPage "160" @default.
• W4323528474 abstract "BackgroundL Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients. Study Question: What is the effectiveness of rivaroxaban versus the standard of care (SOC; low-molecular-weight heparin, unfractionated heparin, warfarin) among LRPE patients in the Veterans Health Administration? Study Design: Adult patients with continuous health plan enrollment for ≥12 months pre- and 3 months post-inpatient PE diagnosis (index date=discharge date) between October 1, 2011- June 30, 2015 and an anticoagulant claim during the index hospitalization were included. Measures and Outcomes Patients scoring 0 points on the simplified Pulmonary Embolism Stratification Index were considered low-risk and were stratified into SOC and rivaroxaban cohorts. Propensity score matching (PSM) was used to compare hospital-acquired complications (HACs), PE-related outcomes (recurrent venous thromboembolism, major bleeding, and death), and healthcare utilization and costs between the rivaroxaban and SOC cohorts. Results: Among 6746 PE patients, 1918 were low-risk; of these, 73 were prescribed rivaroxaban, 1546 were prescribed SOC, and 299 were prescribed other anticoagulants during the index hospitalization. After 1:3 PSM, 64 rivaroxaban and 192 SOC patients were included. During the index hospitalization, rivaroxaban users (versus SOC) had similar inpatient length of stay (LOS; 7.0 vs 6.7 days, standardized difference [STD]=1.8) but fewer HACs (4.7% vs 10.4%; STD: 21.7). In the 90-day post-discharge period, PE-related outcome rates were similar between the cohorts (all p>0.05). However, rivaroxaban users had fewer outpatient (15.9 vs 20.4; p=0.0002) visits per patient as well as lower inpatient ($765 vs $2,655; p<0.0001), pharmacy ($711 vs $1,086; p=0.0033), and total costs ($6,270 vs $9,671; p=0.0027). Conclusions: LRPE patients prescribed rivaroxaban had similar index LOS and PE-related outcomes, but fewer HACs, and lower total costs than those prescribed SOC." @default.
• W4323528474 created "2023-03-09" @default.
• W4323528474 creator A5012212211 @default.
• W4323528474 creator A5012278873 @default.
• W4323528474 creator A5022935489 @default.
• W4323528474 creator A5040117870 @default.
• W4323528474 creator A5053647027 @default.
• W4323528474 creator A5064447813 @default.
• W4323528474 creator A5065282629 @default.
• W4323528474 creator A5087850384 @default.
• W4323528474 date "2023-01-01" @default.
• W4323528474 modified "2023-09-28" @default.
• W4323528474 title "Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care" @default.
• W4323528474 cites W1016348072 @default.
• W4323528474 cites W1518286462 @default.
• W4323528474 cites W1972729446 @default.
• W4323528474 cites W1978722902 @default.
• W4323528474 cites W1993721764 @default.
• W4323528474 cites W1994137866 @default.
• W4323528474 cites W2004008456 @default.
• W4323528474 cites W2021100537 @default.
• W4323528474 cites W2027154314 @default.
• W4323528474 cites W2029834520 @default.
• W4323528474 cites W2037037238 @default.
• W4323528474 cites W2043351648 @default.
• W4323528474 cites W2048813732 @default.
• W4323528474 cites W2067254496 @default.
• W4323528474 cites W2080662564 @default.
• W4323528474 cites W2097561850 @default.
• W4323528474 cites W2098364806 @default.
• W4323528474 cites W2102535207 @default.
• W4323528474 cites W2105878388 @default.
• W4323528474 cites W2107004415 @default.
• W4323528474 cites W2110134277 @default.
• W4323528474 cites W2110454283 @default.
• W4323528474 cites W2117662968 @default.
• W4323528474 cites W2128617715 @default.
• W4323528474 cites W2130199362 @default.
• W4323528474 cites W2139393300 @default.
• W4323528474 cites W2154156055 @default.
• W4323528474 cites W2166361233 @default.
• W4323528474 cites W2234970031 @default.
• W4323528474 cites W2355838579 @default.
• W4323528474 cites W2512789725 @default.
• W4323528474 cites W2513176639 @default.
• W4323528474 cites W2533752036 @default.
• W4323528474 cites W2534359728 @default.
• W4323528474 cites W4233613692 @default.
• W4323528474 cites W4236641504 @default.
• W4323528474 cites W4247552196 @default.
• W4323528474 doi "https://doi.org/10.36469/jheor.2019.9936" @default.
• W4323528474 hasPublicationYear "2023" @default.
• W4323528474 type Work @default.
• W4323528474 citedByCount "0" @default.
• W4323528474 crossrefType "journal-article" @default.
• W4323528474 hasAuthorship W4323528474A5012212211 @default.
• W4323528474 hasAuthorship W4323528474A5012278873 @default.
• W4323528474 hasAuthorship W4323528474A5022935489 @default.
• W4323528474 hasAuthorship W4323528474A5040117870 @default.
• W4323528474 hasAuthorship W4323528474A5053647027 @default.
• W4323528474 hasAuthorship W4323528474A5064447813 @default.
• W4323528474 hasAuthorship W4323528474A5065282629 @default.
• W4323528474 hasAuthorship W4323528474A5087850384 @default.
• W4323528474 hasBestOaLocation W43235284741 @default.
• W4323528474 hasConcept C126322002 @default.
• W4323528474 hasConcept C177713679 @default.
• W4323528474 hasConcept C17923572 @default.
• W4323528474 hasConcept C194828623 @default.
• W4323528474 hasConcept C2776265017 @default.
• W4323528474 hasConcept C2776301958 @default.
• W4323528474 hasConcept C2776884760 @default.
• W4323528474 hasConcept C2777557582 @default.
• W4323528474 hasConcept C2778205648 @default.
• W4323528474 hasConcept C2778661090 @default.
• W4323528474 hasConcept C2779161974 @default.
• W4323528474 hasConcept C71924100 @default.
• W4323528474 hasConceptScore W4323528474C126322002 @default.
• W4323528474 hasConceptScore W4323528474C177713679 @default.
• W4323528474 hasConceptScore W4323528474C17923572 @default.
• W4323528474 hasConceptScore W4323528474C194828623 @default.
• W4323528474 hasConceptScore W4323528474C2776265017 @default.
• W4323528474 hasConceptScore W4323528474C2776301958 @default.
• W4323528474 hasConceptScore W4323528474C2776884760 @default.
• W4323528474 hasConceptScore W4323528474C2777557582 @default.
• W4323528474 hasConceptScore W4323528474C2778205648 @default.
• W4323528474 hasConceptScore W4323528474C2778661090 @default.
• W4323528474 hasConceptScore W4323528474C2779161974 @default.
• W4323528474 hasConceptScore W4323528474C71924100 @default.
• W4323528474 hasLocation W43235284741 @default.
• W4323528474 hasOpenAccess W4323528474 @default.
• W4323528474 hasPrimaryLocation W43235284741 @default.
• W4323528474 hasRelatedWork W1866105834 @default.
• W4323528474 hasRelatedWork W1964152230 @default.
• W4323528474 hasRelatedWork W2019616867 @default.
• W4323528474 hasRelatedWork W2085542854 @default.
• W4323528474 hasRelatedWork W2355421283 @default.
• W4323528474 hasRelatedWork W2741766490 @default.
• W4323528474 hasRelatedWork W3031049035 @default.

• next